[New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
PMID: 33546873 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - February 2, 2021 Category: Cancer & Oncology Authors: Minot-This MS, Edeline J Tags: Bull Cancer Source Type: research

[Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
PMID: 33546874 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - February 2, 2021 Category: Cancer & Oncology Authors: Saillant A, Flippot R Tags: Bull Cancer Source Type: research

[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
PMID: 33531153 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 30, 2021 Category: Cancer & Oncology Authors: Rousseau A, Thieblemont C Tags: Bull Cancer Source Type: research

[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
PMID: 33531154 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 30, 2021 Category: Cancer & Oncology Authors: Reich M, Coutzac C Tags: Bull Cancer Source Type: research

[Current status of clinical practice guidelines on palliative sedation for adults in French-speaking countries].
CONCLUSION: The quantity and volume of the guidelines found and the heterogeneity of the terminology prevented a detailed analysis of the content of the texts. An analysis must be performed using a synchronic approach only and focusing on a specific element of one type of sedation. PMID: 33461728 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 15, 2021 Category: Cancer & Oncology Authors: Tomczyk M, Viallard ML, Beloucif S Tags: Bull Cancer Source Type: research

[Predictive factors of maintain of employment and return to work after cancer].
Abstract BACKGROUND: Return-to-work after cancer depends on several factors related to the disease but also other socio-professional factors. The primary aim of this study was to identify socio-demographic, disease related and professional factors influencing the return-to-work process. METHODS: It was a prospective and descriptive study reporting the return-to-work process in 89 cancer patients, in a professional activity age, who had cancer treatment and a follow up in the Oncology department in Tahar Maamouri Teaching Hospital of Nabeul, between September 2015 to December 2019. RESULTS: Our ...
Source: Bulletin du Cancer - January 14, 2021 Category: Cancer & Oncology Authors: Mersni M, Belfkih H, Bani M, Youssef I, Rais H Tags: Bull Cancer Source Type: research

Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network.
Abstract Sarcomas are a rare heterogeneous group of malignant neoplasms that can arise in almost any anatomic site and any age. Close collaboration among adult and pediatric cancer specialists in the management of these tumors is of foremost importance. In this review, we present the current multidisciplinary organization in care of patients with sarcoma in France and we review the main advances made in the last decades in systemic and radiotherapy treatment in the main sarcoma types diagnosed in children, adolescents and young adults (AYA), thanks to the international collaboration. PMID: 33455736 [PubMed - ...
Source: Bulletin du Cancer - January 14, 2021 Category: Cancer & Oncology Authors: Bompas E, Martin V, Meniai F, Toulmonde M, Marec-Berard P, Claude L, Ducimetiere F, Chargari C, Minard-Colin V, Corradini N, Laurence V, Piperno-Neumann S, Defachelles AS, Bernier V, Italiano A, Orbach D, Blay JY, Gaspar N, Berlanga P Tags: Bull Cancer Source Type: research

[Transition to adulthood: An essential period in the follow up of young patients].
Abstract In recent decades, follow-up of cancer survivors has taken on its full meaning with the gradual improvement in the survival of children and adolescents with cancer. This follow-up is associated specially for adolescents with a multitude of transitions: the transition from therapeutic management to the monitoring for possible relapse, the transition into long-term follow-up after childhood cancer, the transition from a pediatric system to an adult care system. If this transition can be perceived as difficult by patients, it gives young people the opportunity to access more autonomous follow-up and support ...
Source: Bulletin du Cancer - January 11, 2021 Category: Cancer & Oncology Authors: Vergne C, Blin N, Mallet J, Thomas B, Moles MP, Schmidt A, Proust S Tags: Bull Cancer Source Type: research

An overview of autophagy: Mechanism, regulation and research progress.
Abstract Autophagy refers to the formation of autophagosomes by membrane wrapping part of the cytoplasm and the organelles and proteins that need to be degraded in the cells. Autophagosomes are fused with lysosomes to form autophagolysosome, which degrade the contents of the inclusions, to achieve cell homeostasis and organelle renewal. The regulatory mechanism of autophagy is complex, and its upstream signaling pathway mainly involves mTOR dependent pathway and mTOR independent pathway (AMPK, PI3K, Ras-MAPK, p53, PTEN, endoplasmic reticulum stress). Autophagy is a phenomenon of "self-eating" in cells. A...
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Cao W, Li J, Yang K, Cao D Tags: Bull Cancer Source Type: research

[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Abstract The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (KymriahTM) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (YescartaTM) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologo...
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Beauvais D, Bachy E, Baruchel A, Bay JO, Caillot D, Cartron G, Damaj G, Furst S, Le Gouill S, Morschhauser F, Rabian F, Rubio MT, Thieblemont C, Yakoub-Agha I Tags: Bull Cancer Source Type: research

Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
CONCLUSION: The taxanes' toxicity profile in Tunisian patients is characterized by more frequent digestive and nail toxicities and less frequent hematological toxicities, dose reduction and treatment delays than other populations. PMID: 33423777 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Ben Nasr S, Zribi A, Ben Hassen M, Doghri Y, Ben Abdallah I, Trigui E, Fendri S, Ayari J, Balti M, Haddaoui A Tags: Bull Cancer Source Type: research

Inventaire des l ésions de l’ADN et principaux mécanismes de réparation de l’ADN.
Inventaire des lésions de l’ADN et principaux mécanismes de réparation de l’ADN. Bull Cancer. 2021 Jan 07;: Authors: Pourquier P PMID: 33423778 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Pourquier P Tags: Bull Cancer Source Type: research

[DNA polymerase θ targeting in oncology].
[DNA polymerase θ targeting in oncology]. Bull Cancer. 2021 Jan 07;: Authors: Hoffmann JS PMID: 33423779 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Hoffmann JS Tags: Bull Cancer Source Type: research

[Squamous cell anal carcinoma. What's next  ?]
[Squamous cell anal carcinoma. What's next ?] Bull Cancer. 2021 Jan 07;: Authors: Kim S, Spehner L, Cabel L, Bidard FC, Borg C Abstract Despite its status as a rare disease, the incidence of the squamous cell carcinoma of the anus (SCCA) is surging, especially in its metastatic form. In addition, the prognosis of initially localized diseases has not substantially changed since the 1970s with a recurrence rate of between 25-40 % after the chemoradiotherapy. The updated data from 115 patients included in the Epitopes-HPV01 and Epitopes-HPV02 trials, confirm the modified regimen ...
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Kim S, Spehner L, Cabel L, Bidard FC, Borg C Tags: Bull Cancer Source Type: research

Silencing of BCSG1 with specific siRNA via nanocarriers for breast cancer treatment.
Abstract Breast cancer is the most common cancer diagnosed in women worldwide. The current treatments for breast cancer, including surgery, radiotherapy and chemotherapy aim to destroy cancer cells, whereas they also cause damage to normal tissues and cells. Thus, an effective, safe and specific breast cancer treatment is urgently needed. The breast cancer-specific gene 1 (BCSG1) has been shown to be specific for the development of breast cancer and is a target for breast cancer diagnosis and treatment. It is expected to silence the expression of BCSG1 at the gene level for the purpose of treating breast cancer. T...
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Yang C, Cheng X, Shen P Tags: Bull Cancer Source Type: research

Une fraude exemplaire.
PMID: 33423782 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Robert J Tags: Bull Cancer Source Type: research

[Diseases of repair].
PMID: 33423783 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 7, 2021 Category: Cancer & Oncology Authors: Girard PM Tags: Bull Cancer Source Type: research

[In silico exploration of databases is no longer a fighting sport].
PMID: 33422338 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 6, 2021 Category: Cancer & Oncology Authors: Robert J Tags: Bull Cancer Source Type: research

Amid darkness, light will prevail – a report on the 2020 annual SFC meeting on “Dark genome and Cancer”.
Amid darkness, light will prevail – a report on the 2020 annual SFC meeting on “Dark genome and Cancer”. Bull Cancer. 2021 Jan 06;: Authors: Kleshnin A, Monet L, Plays M, Vaysset H, Rougeulle C, Vagner S PMID: 33422339 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 6, 2021 Category: Cancer & Oncology Authors: Kleshnin A, Monet L, Plays M, Vaysset H, Rougeulle C, Vagner S Tags: Bull Cancer Source Type: research

[Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
g M Abstract Compared with other breast cancer subtypes, patients with metastatic triple-negative breast cancer (TNBC) are younger and have a worst overall survival with a median of 15 to 18 months. These tumors have long suffered from a purely negative definition, but the last few years have witnessed many breakthrough genomic and molecular findings, that could dramatically improve our understanding of the biological heterogeneity of TNBC. Moreover, based on these genomic analyses, new generation of clinical trials, using many innovative therapies directed against novel targets, had been conducted. Some TNBC have...
Source: Bulletin du Cancer - January 6, 2021 Category: Cancer & Oncology Authors: Dalenc F, Sarradin V, Nicolaï V, Franchet C, Ung M Tags: Bull Cancer Source Type: research

[What should we remember from 2020?]
n du cancer Abstract The editorial committee of the Bulletin du Cancer is proud to comply with his annual analysis of some of the worldwide updates in oncology that emerge in 2020. We know that all new breakthroughs will not be addressed and apologise for not being comprehensive, but we hope that the topics deciphered herein will bring the reader interesting information in his daily practice in gyneco-oncology, uro-oncology, neuro-oncology, digestive oncology, pneumo-oncology, hemato-oncology, pediatric oncology, or in palliative care. PMID: 33419531 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - January 5, 2021 Category: Cancer & Oncology Authors: Bay JO, Andre T, Bouleuc C, Gandemer V, Magne N, Orbach D, Pellier I, Penel N, Rodrigues M, Thariat J, Thiery-Villemin A, Wisley M, L'Allemain G, Robert J, Comité de rédaction du Bulletin du cancer Tags: Bull Cancer Source Type: research

[Stereotactic radiotherapy in urologic cancers: Reports from the 3rd international meeting of the Groupe Francophone de Radioth érapie Urologique (GFRU)].
[Stereotactic radiotherapy in urologic cancers: Reports from the 3rd international meeting of the Groupe Francophone de Radiothérapie Urologique (GFRU)]. Bull Cancer. 2020 Dec 24;: Authors: Perennec T, Supiot S PMID: 33358745 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 24, 2020 Category: Cancer & Oncology Authors: Perennec T, Supiot S Tags: Bull Cancer Source Type: research

[Discrepancies in medical textbooks and their impact on medical school students].
CONCLUSIONS: Discrepancies between official textbook are frequent, generate anxiety in students and impact learning experience. PMID: 33358746 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 24, 2020 Category: Cancer & Oncology Authors: Cohen R, Renaud MC, Huguet F, André T, Duguet A, Steichen O Tags: Bull Cancer Source Type: research

Predictive resistance factors  in lung cancer patients treated with Nivolumab. Retrospective study.
CONCLUSION: This study enriches data about immunotherapy in real-life in NSCLC. Prognostic resistance factors still seem complicated to identify. The high rate of taxane responders in post immunotherapy in this retrospective cohort support the use of taxane in therapeutic escape. PMID: 33358747 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 24, 2020 Category: Cancer & Oncology Authors: Bernichon E, Tissot C, Bayle-Bleuez S, Rivoirard R, Bouleftour W, Forest F, Tinquaut F, Mery B, Fournel P Tags: Bull Cancer Source Type: research

[Hepatitis B vaccine and liver cancer].
lim F Abstract Hepatitis B Virus (HBV) chronic infection contributes to a high risk of hepatocellular cancer (HCC) development. HBV is a strong cancer inducer, due to natural history of infection, virological characteristics and viral DNA integrations events in host genome. Prolonged infection and high viral loads, particularly frequent in patients infected in childhood, are risk factors of HCC development for patients with HBV chronic infection. A HBV vaccine, based on immunization against the surface protein HBs, showed a strong efficacy to prevent chronic HBV infection. The development of universal neonatal vac...
Source: Bulletin du Cancer - December 23, 2020 Category: Cancer & Oncology Authors: Lebossé F, Zoulim F Tags: Bull Cancer Source Type: research

[Impact of patient testimony in the education of medicine and pharmacy students].
Abstract The initiative from patients suffering from cancer or having had the disease in speaking about their illness to medical students during an internship in a cancer control center of the faculty of medicine and to pharmacy students at the university of Strasbourg was implemented in 2014. This action was coordinated by the French Cancer League as part of the National French cancer plan 3. After training, ten patients teachers were able to freely and spontaneously explain their diagnostic and therapeutic journey as well as their feelings about the disease and their relationship with their oncologists in front ...
Source: Bulletin du Cancer - December 23, 2020 Category: Cancer & Oncology Authors: Schraub S, Blaise P, Noel G, Casset A, Etienne-Selloum N, Da Silva F, Marchal P, Schneider G, Bergerot P Tags: Bull Cancer Source Type: research

[Third French Cancer Plan: Six years at the service of the French people].
Abstract The implementation of the third Cancer Plan, which began in January 2014, was completed in 2019. With nearly 90% of the actions carried out, this Plan was marked by the collective mobilisation of all stakeholders to reduce the burden of cancer in our country. Real successes have been recorded. But the progress made must not make us forget the pain and suffering endured by those affected by this disease, their families, loved ones and caregivers. Cancer continues to be a life-changing experience for those who face it. In this fight, progress in medicine, research, the quality and safety of care, progress i...
Source: Bulletin du Cancer - December 23, 2020 Category: Cancer & Oncology Authors: Jullian O, Cvetojevic D Tags: Bull Cancer Source Type: research

[Interactions optimization between pediatricians and adults' physicians for patient benefit in oncology].
PMID: 33342542 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 17, 2020 Category: Cancer & Oncology Authors: Gandemer V, Orbach D, Pellier I Tags: Bull Cancer Source Type: research

[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
PMID: 33308986 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 10, 2020 Category: Cancer & Oncology Authors: Calleja A, Bouclet F Tags: Bull Cancer Source Type: research

[MR-Linac: The era of personalised radiation therapy].
PMID: 33308847 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 8, 2020 Category: Cancer & Oncology Authors: Tallet A, Tyran M, Salem N, Fau P Tags: Bull Cancer Source Type: research

[Innovation in radiotherapy in 2021].
PMID: 33303195 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 7, 2020 Category: Cancer & Oncology Authors: Masson I, Dutreix M, Supiot S Tags: Bull Cancer Source Type: research

[Early salvage radiotherapy in prostate cancer: A future standard treatment?]
;ro L PMID: 33280838 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Labidi M, Hennequin C, Quéro L Tags: Bull Cancer Source Type: research

[Are telomeres and telomerase still relevant targets in oncology?]
an É PMID: 33256968 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 27, 2020 Category: Cancer & Oncology Authors: Mergny JL, Guittat L, Ségal-Bendirdjian É Tags: Bull Cancer Source Type: research

[Regional cancers networks, collaborative work in adults and pediatricians].
Abstract Regional cancer networks missions have been defined by successive "Plan Cancer" and are focused on coordination and the safety and quality of care. Regional pediatric oncology networks, considering the specific care pathways, have these same coordination missions. The examples of partnership of the oncoped-PL (Pays de Loire) and oncomip (Occitanie) networks are successful collaboration models. PMID: 33198952 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 13, 2020 Category: Cancer & Oncology Authors: Thebaud E, Bertozzi AI, Bauvin E, Empereur F Tags: Bull Cancer Source Type: research

[New European approvals: Durvalumab - In first line metastatic small-cell lung cancer].
PMID: 33187682 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 10, 2020 Category: Cancer & Oncology Authors: El Kaddissi A, Basse C Tags: Bull Cancer Source Type: research

[Quality assessment of CAR T-cell activity: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
tin N Abstract CAR T-cells are anti-cancer immunocellular therapy drugs that involve reprogramming the patient's T-cells using a transgene encoding a chimeric antigen receptor (CAR). Although CAR T-cells are cellular therapies, the organization for manufacturing and delivering these medicinal products is in many ways different from the one for hematopoietic cell grafts or donor lymphocyte infusions. The implementation of this innovative therapy is recent and requires close coordination between clinical teams, the therapeutic apheresis unit, the cell therapy unit, the pharmaceutical laboratory, and pharmacy. Apart ...
Source: Bulletin du Cancer - November 10, 2020 Category: Cancer & Oncology Authors: Duléry R, Lacassagne MN, Giraud C, Ader V, Beaumont JL, Carnoy S, Carpentier A, Fegueux N, Gibault-Joffe C, Guerout-Verite MA, Huynh TNP, Lewalle P, Perrin A, Plaza-Milhe S, Bonnin A, Yakoub-Agha I, Contentin N Tags: Bull Cancer Source Type: research

[Genomic instability, the engine of oncogenesis].
PMID: 33187684 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 10, 2020 Category: Cancer & Oncology Authors: Robert J Tags: Bull Cancer Source Type: research

Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres.
CONCLUSION: For patients with liver metastases from uveal melanoma ineligible for local treatments, TACE using melphalan may be performed as first line therapy in metastatic miliary disease from uveal melanomas with careful supportive care. PMID: 33183739 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 9, 2020 Category: Cancer & Oncology Authors: Carle X, Gastaud L, Salleron J, Tardy MP, Caujolle JP, Thyss A, Thariat J, Chevallier P Tags: Bull Cancer Source Type: research

[What's new in the management of meningeal solitary fibrous tumor/hemangiopericytoma?]
Abstract Meningeal fibrous solitary tumors/hemangiopericytoma are rare and aggressive mesenchymal neoplasms considered as sarcomas. They represent less than 1% of intracranial tumors and derive from the pericytes of Zimmerman which permit capillary contraction. They tend to occur more often in males in the fifth decade. They are often revealed by intracranial hypertension. Some scannographic and MRI characteristics permit to distinguish meningeal fibrous solitary tumor/hemangiopericytoma from other meningeal tumors. Meningeal hemangiopericytoma and fibrous solitary tumors were considered as different entities unti...
Source: Bulletin du Cancer - November 4, 2020 Category: Cancer & Oncology Authors: Lottin M, Escande A, Peyre M, Sevestre H, Maurage CA, Chauffert B, Penel N Tags: Bull Cancer Source Type: research

[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
PMID: 33169692 [PubMed - in process] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 1, 2020 Category: Cancer & Oncology Authors: Delaye M, Rodrigues M Tags: Bull Cancer Source Type: research

Standard of care for adult Wilms tumor? From adult urologist to pediatric oncologist. A retrospective review.
uur A Abstract Nephroblastoma or Wilms tumor, a common embryonal tumor in children, can occasionally occur in adults. The survival of patients older than 18 years is reported to be significantly inferior to that of pediatric patients. Establishing a diagnosis for these rare tumors can be challenging for both clinicians and pathologists, who are not accustomed to considering Wilms tumor as a potential differential in adults. This leads to misdiagnosis and a subsequent delay in the initiation of appropriate therapy. The standard of care is not well established for Wilms tumors in adults. We provide here a comprehens...
Source: Bulletin du Cancer - October 28, 2020 Category: Cancer & Oncology Authors: Sudour-Bonnange H, Coulomb-Lherminé A, Fantoni JC, Escande A, Brisse HJ, Thebaud E, Verschuur A Tags: Bull Cancer Source Type: research

[3rd colloquium on fundamental research in paediatric oncology].
Grosset CF PMID: 33097208 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 20, 2020 Category: Cancer & Oncology Authors: Trézéguet V, Lesjean S, Veschambre P, Auguste P, Turcq B, Ducassou S, Merched A, Grosset CF Tags: Bull Cancer Source Type: research

[Oncologic supportive care for a personalized support of all patients].
che L Abstract Ever since the officialization of oncologic supportive care by the DHOS circular in February 22nd, 2005 and measure 42 of the 2003-2007 Cancer Plan, their content has been enriched for inpatients and outpatients. A guaranteed care package was determined in February 2017 following a study lead by AFSOS and INCa. It adds adapted physical activity and sexual health support to basic supportive care such as pain relief, nutrition, psychology, social support. Supportive cares in pediatric oncology were defined in March 2004. They always were part of holistic pediatric care. The offer in supportive care fo...
Source: Bulletin du Cancer - October 20, 2020 Category: Cancer & Oncology Authors: Lervat C, Vanlemmens L, Bondil P, Jacquot J, Scotté F, Gofti-Laroche L Tags: Bull Cancer Source Type: research

[Patients on oral anticancer drugs and coordinated pathway: CHIMORAL, feedback from care providers].
DISCUSSION: This intervention has strengthened the networks' links with primary care providers. The use of the community-based care system for adverse events was more frequent, with improved detection and patient awareness, with no observed impact on compliance. A proposed evolution is to maintain an in-home assessment for all patients and to define a frequency and duration of follow-up according to the patient's profile. PMID: 33097210 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 20, 2020 Category: Cancer & Oncology Authors: Maritaz C, Napoly L, Burnel S, Lotz JP Tags: Bull Cancer Source Type: research

[Study of representations of end-of-life platelet transfusion by its protagonists: Patients, nurses and hematologic oncologists].
This study aims to describe these representations of platelet transfusion in a context of a severe and advanced hematologic malignancy through the social representation of its protagonists. METHODS: A qualitative study, using the associative network method and including three groups of 15 participants (patients with an advanced hematologic malignancy, regularly transfused in platelet concentrates; nurses and hematologic oncologists) from four hematology centers was conducted between February and April 2019. Analysis was carried out using IraMuTeQ software. RESULTS: Patients expect platelet transfusion to have a d...
Source: Bulletin du Cancer - October 19, 2020 Category: Cancer & Oncology Authors: Moracchini J, Godard-Marceau A, Aubry R Tags: Bull Cancer Source Type: research

[New European approvals: Glasdegib for Acute myeloid leukemia].
aud L PMID: 33070952 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 15, 2020 Category: Cancer & Oncology Authors: Barrière S, Gastaud L Tags: Bull Cancer Source Type: research

[Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology].
Abstract Genomic instability is one of the main properties of tumour development, promoting first the acquisition of genetic alterations and thus carcinogenesis. Then, the chronic and anarchic proliferation of cancer cells also supports and contributes to this instability allowing a continuous evolution of the tumour. The accumulation of mutations resulting from that instability contributes to tumour heterogeneity that occurs in a specific environment. The resulting diversity of oncogenic drivers further complicates the characterization of the origin of cancer cells dysfunction and consequently therapeutic decisio...
Source: Bulletin du Cancer - October 15, 2020 Category: Cancer & Oncology Authors: Billaud A, Chevalier LM, Campone M, Morel A, Bigot F Tags: Bull Cancer Source Type: research

[Perceptions and attitudes of nurses on emotional and sexual lives of cancer patients].
CONCLUSION: Nurses must acknowledge the existence of sexual health issues in cancer patients by rectifying their perceptions of sexuality, improving their knowledge and management of care, by addressing the issue of sexual health early enough. PMID: 33069338 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 14, 2020 Category: Cancer & Oncology Authors: Mbalè E, D'Hondt L, Vastrade C, Coppieters Y Tags: Bull Cancer Source Type: research

[Crohn's disease and autologous hemapoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
rge D Abstract Crohn's Disease (CD) is an auto-inflammatory disease, which may involve the entire gastro-intestinal tract. CD is diagnosed on several clinical, biological, endoscopic and histological criteria. First line therapy is based on oral or iv steroids. In case of steroids dependence or resistance, several types of immunosuppressive or immunomodulating therapies are available: classical antimetabolites (thiopurines or methotrexate) or monoclonal antibodies against TNFα, against interleukin 12/23 or against integrin. Nonetheless, Crohn's disease may remain active despite the use of several lines of th...
Source: Bulletin du Cancer - October 13, 2020 Category: Cancer & Oncology Authors: Puyade M, Treton X, Alric L, Badoglio M, Castilla Llorente C, Fotsing G, Marjanovic Z, Rovira M, Terriou L, Torregrosa Díaz Jose M, Tran-Minh ML, Allez M, Pugnet G, Laharie D, Yakoub-Agha I, Farge D Tags: Bull Cancer Source Type: research

[Palliative care medical consultation in a hematology department. Feedback and critical reflection on a year of practice].
We describe the benefits that can be anticipated when collaboration increases between hematology and palliative care, including early on in the course of disease. It is now up to policy-makers to establish priorities regarding the allocation of health resources, in particular regarding end-of-life. This requires identifying patient needs, optimizing patient access to specialized palliative care, and improving the pertinence of palliative care interventions as they cannot be generalized. PMID: 33059871 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 12, 2020 Category: Cancer & Oncology Authors: Prod'homme C Tags: Bull Cancer Source Type: research